CTNNB1 and hepatocellular carcinoma: Approximately half of the patients with HCC exhibit aberrant activation of the Wnt/β-catenin pathway, and these cases are further divided into two molecular subtypes: the CTNNB1 class (21.5%) and the Wnt-TGFβ class (27.6%).